Chalcone

Chalcone

SCHEMBL454583

O=C(/C=C\c1ccccc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 10/20 1.00
MAPT P10636 6/20 1.00
MAOB P27338 6/20 1.00
LMNA P02545 2/20 1.00
BCHE P06276 2/20 1.00
TNFRSF1A P19438 2/20 1.00
PLIN1 O60240 1/20 1.00
ACHE P22303 1/20 1.00
RECQL P46063 1/20 1.00
PLIN5 Q00G26 1/20 1.00
ABHD5 Q8WTS1 1/20 1.00
CYP3A4 P08684 5/20 0.78
KMT2A Q03164 4/20 0.78
HSPD1 P10809 3/20 0.78
HSPE1 P61604 3/20 0.78
NFKB1 P19838 2/20 0.78
RAB9A P51151 2/20 0.78
NFKB2 Q00653 2/20 0.78
RELA Q04206 2/20 0.78
MEN1 O00255 2/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chalcone SCHEMBL29922932 1.00 CYP1B1 (1.00) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL27580 1.00 CYP1B1 (1.00) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL28306720 1.00 CYP1B1 (1.00) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL27581 1.00 CYP1B1 (1.00) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL29396001 1.00 CYP1B1 (1.00) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL2404758 1.00 CYP1B1 (1.00) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL2427445 0.98 CYP1B1 (0.96) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL527181 0.98 CYP1B1 (0.96) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL7861207 0.98 CYP1B1 (0.96) CYP1B1MAPTMAOBLMNABCHE
Chalcone SCHEMBL7653806 0.98 CYP1B1 (0.96) CYP1B1MAPTMAOBLMNABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3164196-B1 TOPICAL FORMULATIONS FOR UV PROTECTION TOPGENIX INC (US) 2021-08-18 EP claimed
EP-2859069-B1 METHOD AND APPARATUS FOR TREATING PETROLEUM EQUIPMENT FERRARA MARCELLO (IT) 2020-10-14 EP claimed
EP-2025324-B1 Method of Quenching Electronic Excitation of Chromophore-Containing Organic Molecules in Photoactive Compositions HALLSTAR INNOVATIONS CORP (US) 2013-08-14 EP claimed
EP-1187865-B1 METHOD FOR PRODUCING OF MATRESSES, UPHOLSTERIES FOR FURNITURE OR CARPET BACKINGS BASF AG (DE) 2005-11-09 EP claimed
EP-0973636-B1 TRANSPARENT ARTICLE WITH RADIAL REFRACTIVE INDEX GRADIENT AND PROCESS FOR ITS MANUFACTURE ESSILOR INT (FR) 2003-01-02 EP claimed
EP-0177122-B1 ACRYLAMIDE DERIVATIVES Nippon Paint Co., Ltd. (JP) 1992-04-01 EP claimed
EP-0262672-B1 NON-LINEAR OPTICAL ARTICLE NIPPON OIL AND FATS COMPANY, LIMITED (JP) 1991-11-27 EP claimed
JP-10026760-A None JP disclosed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12252642-B2 Method for producing cholesteric liquid crystal layer, cholesteric liquid crystal layer, optically anisotropic body, and reflective film FUJIFILM CORPORATION (JP) 2025-03-18 US disclosed
WO-2024247969-A1 DECORATIVE FILM, DISPLAY DEVICE, AND AUTOMOBILE INTERIOR FINISHING 富士フイルム株式会社 2024-12-05 WO disclosed
US-20230026978-A1 PHOTOISOMERIZED COMPOSITIONS OF ANTHOCYANINS AND METHODS OF MAKING AND USE THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2023-01-26 US disclosed
US-20220204850-A1 METHOD FOR PRODUCING CHOLESTERIC LIQUID CRYSTAL LAYER, CHOLESTERIC LIQUID CRYSTAL LAYER, OPTICALLY ANISOTROPIC BODY, AND REFLECTIVE FILM FUJIFILM CORPORATION (JP) 2022-06-30 US disclosed
WO-1994007889-A1 PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS PPG INDUSTRIES, INC. (US) 1994-04-14 WO disclosed
US-5274132-A Photochromic naphthopyran compounds TRANSITIONS OPTICAL, INC. (US) 1993-12-28 US disclosed
EP-0489778-A1 ANTI-INFLAMMATORY ACTIVE INGREDIENTS FOR COSMETIC PREPARATIONS Henkel Kommanditgesellschaft auf Aktien (DE) 1992-06-17 EP disclosed
WO-1991003232-A1 ANTI-INFLAMMATORY ACTIVE INGREDIENTS FOR COSMETIC PREPARATIONS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1991-03-21 WO disclosed
WO-1991002515-A1 ANTI-INFLAMMATORY SUBSTANCES FOR COSMETIC PREPARATION HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1991-03-07 WO disclosed
WO-1991002514-A1 ANTI-INFLAMMATORY ACTIVE SUBSTANCES FOR COSMETIC COMPOSITIONS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1991-03-07 WO disclosed
EP-0233455-A1 Hydrogenation and reduction by means of the hydrocarbon/carbon system BASF Aktiengesellschaft (DE) 1987-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B CYP1B1 230/4885MAPT 3297/4885MAOB 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.